HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
Returns on capital
HLS Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-20.5%
avg -13.9%
ROIC
-3.5%
avg -2.8%
ROA
-9.2%
avg -7.3%
Analysis
ROIC is currently the strongest return metric at -3.5% versus its period average of -2.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Craig Stuart Millian | Chief Executive Officer & Director | USD 1.37M | 58 | — | — |
Brian T. Walsh | Chief Operating Officer | USD 707.68K | — | — | — |
John Hanna | Chief Financial Officer & Non-Independent Director | USD 676.87K | 61 | — | — |
Ryan C. Lennox | Senior VP, General Counsel, Head of Corporate Governance & Corporate Secretary | USD 550.23K | 45 | — | — |
Jason A. Gross | Vice President of Scientific Affairs | USD 423.54K | 61 | — | — |
Patricia Perry | Vice-President of Human Resource | — | 50 | — | — |
David Spence | Vice President & Corporate Controller | — | 58 | — | — |
Dave Mason | Investor Relations Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -2.8% | +11.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.8% over three years. Forward estimates point to Revenue at +11.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does HLS Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about HLS.TO's management, answered from reported figures.
Who manages HLS.TO?
HLS Therapeutics Inc. (HLS.TO) lists 8 active executives. The top listed executive is Jason A. Gross, Vice President of Scientific Affairs.
Continue the stock analysis
Jump to another research area for this company.